ERBB2 and breast carcinoma: A study by Gupta in 2014 showed that in a cross-sectional survey of 160 women with HR+ and HER2- breast cancer, those using hormone therapy reported greater health-related quality of life and treatment satisfaction than women receiving chemotherapy, indicating the benefit of targeted breast cancer treatment over chemotherapy [50].